

COVID-19 Update

As we navigate through the ever evolving COVID-19 situation, our thoughts are with those affected by the virus. We are following the advice of Governments and other public health related agencies to ensure the health and wellbeing of our employees, suppliers, partners, and customers, whilst minimizing the disruption to the processing and delivery of our novel biologic products to patients in need.

What Are We Doing?

Tissue Regenix Group and its subsidiaries, including CellRight Technologies, are adapting the way we approach our business functions as we ensure to implement Government and other public-health related agency advice, including self-isolation and social distancing. Wherever possible, our employees are working from home and any non-urgent business travel has been postponed until further notice. We have also implemented a strict no-visitor policy at all sites unless required for essential maintenance however, in order to continue processing our product portfolio some employees are required on-site. In these circumstances, additional hygiene precautions have been implemented and staggered working patterns have commenced to reduce the potential of contact; the health and safety of all employees and those we work with is paramount. We are also aligned with the recommendations from the American Association of Tissue Banks (AATB) regarding tissue procurement guidelines.

We will continue to monitor this situation closely and work to protect the health and wellbeing of all stakeholders. As further information comes to light, we will look to keep everyone sufficiently updated.

We would also like to take this opportunity to thank you for your ongoing support, especially at this time.

For further information please contact:

enquiries@tissueregenix.com